United States · 
Who invested in Alveus Therapeutics?
Alveus Therapeutics's investors include Omega Funds, Andera Partners, New Rhein, Sanofi and KurmaPartners, and 1 more on record. Omega Funds led its latest round.
United States · Series A startup
Who invested in Alveus Therapeutics
One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Raised 10 months ago
Follow Alveus Therapeutics and see its new rounds in your feed.Start following
Funding summaryUpdated 31 Oct 2026
$160Mraised across 1 round since 2026, from 1 source
- Latest round
- Series A, $160MJan 2026
- Led by
- Omega Funds and Andera Partnersand 1 more
- Investors
- 6 (3 led)
The rounds
- Jan 2026Series A$160M
Reported by Avego ManagementSEC filing: $57M sold, first sale Dec 2025
Everyone who backed them
Avego Bioscience CapitalPrivate equity1round
Missing a round, or an investor who was in one? Tell us.
Quick answers about Alveus Therapeutics
How much has Alveus Therapeutics raised?
Alveus Therapeutics has raised $160M across 1 round since 2026.
When did Alveus Therapeutics last raise?
Alveus Therapeutics's most recent round was a Series A of $160M in Jan 2026, led by Omega Funds.
What was Alveus Therapeutics's biggest round?
Its most recent round, $160M in Jan 2026, is also its largest on record.
Who backed Alveus Therapeutics first?
Alveus Therapeutics's first round on record, in Jan 2026, was backed by Omega Funds, Andera Partners and New Rhein and 3 others.
What stage is Alveus Therapeutics at?
Alveus Therapeutics's latest named round is a Series A, in Jan 2026.
Where is Alveus Therapeutics based?
Alveus Therapeutics is based in the United States.
Who led Alveus Therapeutics's rounds?
Omega Funds led the Series A in 2026.
Companies like Alveus Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.